CASI Ph.: targeting 50% growth in Evomela sales

Seite 1 von 1 Neuester Beitrag: 27.05.22 13:13
Eröffnet am:	25.02.21 17:55	von: banditolino	Anzahl Beiträge:	4
Neuester Beitrag:	27.05.22 13:13	von: Vassago	Leser gesamt:	2.977
Forum:	Börse		Leser heute:	2
Bewertet mit:

Optionen


Antwort einfügen
zum neuesten Beitrag
Börsenforum

banditolino: CASI Ph.: targeting 50% growth in Evomela sales

25.02.21 17:55

"CASI is a U.S. NASDAQ-listed biopharmaceutical company with a platform to develop and accelerate the launch of pharmaceutical products and innovative therapeutics in China, the U.S., and throughout the world. We have offices in Rockville, Maryland, and a wholly owned subsidiary in Beijing, China, through which substantially all of our operations are conducted."